Insmed (INSM) Enterprise Value (2010 - 2026)
Insmed (INSM) posted quarterly Enterprise Value of -$1.2 billion for Q1 2026, down 2.01% year-over-year from -$1.2 billion in Q1 2025, and up 14.44% quarter-over-quarter from -$1.4 billion in Q4 2025.
Insmed (INSM) Enterprise Value (2010 - 2026) Analysis & Trends
Insmed's Enterprise Value history runs 17 years deep, the most recent figure standing at -$1.2 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 2.01% year-over-year to -$1.2 billion; the TTM figure through Mar 2026 stood at -$1.2 billion (down 2.01% YoY), while the FY2025 annual figure was -$1.4 billion, changed 0.26% from the prior year.
- Enterprise Value for Q1 2026 stood at -$1.2 billion, up from -$1.4 billion in the prior quarter.
- The five-year high for Enterprise Value was -$513.3 million in Q3 2022, with the low at -$1.9 billion in Q2 2025.
- The 5-year median for Enterprise Value is -$1.1 billion (2022), against an average of -$1.1 billion.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value surged 40.35% in 2024, then slumped 101.34% in 2025.
- Insmed's Enterprise Value stood at -$1.1 billion in 2022, then soared by 32.03% to -$780.4 million in 2023, then plunged by 83.72% to -$1.4 billion in 2024, then increased by 0.26% to -$1.4 billion in 2025, then gained by 14.44% to -$1.2 billion in 2026.
- Business Quant data shows INSM's Enterprise Value at -$1.2 billion in Q1 2026, -$1.4 billion in Q4 2025, and -$1.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.15 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.16 Bn |
| Mar 31, 2026 | -1.22 Bn |
| Dec 31, 2025 | -1.43 Bn |
| Sep 30, 2025 | -1.68 Bn |
| Jun 30, 2025 | -1.86 Bn |
| Mar 31, 2025 | -1.20 Bn |
| Dec 31, 2024 | -1.43 Bn |
| Sep 30, 2024 | -1.47 Bn |
| Jun 30, 2024 | -1.25 Bn |
| Mar 31, 2024 | -595.70 Mn |
| Dec 31, 2023 | -780.45 Mn |
| Sep 30, 2023 | -785.95 Mn |
| Jun 30, 2023 | -917.77 Mn |
| Mar 31, 2023 | -998.68 Mn |
| Dec 31, 2022 | -1.15 Bn |
| Sep 30, 2022 | -513.26 Mn |
| Jun 30, 2022 | -554.89 Mn |
| Mar 31, 2022 | -635.12 Mn |
| Dec 31, 2021 | -716.78 Mn |
| Sep 30, 2021 | -846.60 Mn |